Association between carnitine deficiency and the erythropoietin resistance index in patients undergoing peritoneal dialysis: a cross-sectional observational study

References

• Yang SK, Xiao L, Song PA, et al. Effect of L-carnitine therapy on patients in maintenance hemodialysis: a systematic review and meta-analysis. J Nephrol. 2014;27:317–329.
   PubMed Web of Science ®Google Scholar
• Kamei D, Tsuchiya K, Nitta K, et al. Association between resistance to erythropoiesis-stimulating agents and carnitine profile in patients on maintenance haemodialysis. Nephrology (Carlton, Vic). 2018;23:737–743.
   PubMed Web of Science ®Google Scholar
• Schreiber BD. Debate forum: levocarnitine therapy is rational and justified in selected dialysis patients. Blood Purif. 2006;24:128–139.
   PubMed Web of Science ®Google Scholar
• Rebouche CJ, Engel AG. Carnitine metabolism and deficiency syndromes. Mayo Clin Proc. 1983;58:533–540.
   PubMed Web of Science ®Google Scholar
• Naseri M, Mottaghi Moghadam Shahri H, Horri M, et al. absolute and relative carnitine deficiency in patients on hemodialysis and peritoneal dialysis. Iran J Kidney Dis. 2016;10:36–43.
   PubMed Web of Science ®Google Scholar
• Zhang YM, Zhuo L, Hu J, et al. Clinical significance of different carnitine levels for improving the prognosis of patients undergoing hemodialysis. Ren Fail. 2016;38:1654–1658.
   PubMed Web of Science ®Google Scholar
• Hatanaka Y, Higuchi T, Akiya Y, et al. Prevalence of carnitine deficiency and decreased carnitine levels in patients on hemodialysis. Blood Purif. 2019;47 :38–44.
   PubMed Web of Science ®Google Scholar
• Khositseth A, Jirasakpisarn S, Pakakasama S, et al. Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy. Indian J Med Paediatr Oncol. 2011;32:38–42.
   PubMedGoogle Scholar
• Evans AM, Faull RJ, Nation RL, et al. Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney Int. 2004;66:1527–1534.
   PubMed Web of Science ®Google Scholar
• Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis. 2003;41:S13–S26.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Abe M, Yamazaki T, et al. Levocarnitine improves cardiac function in hemodialysis patients with left ventricular hypertrophy: a randomized controlled trial. Am J Kidney Dis. 2016;67:260–270.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Joki N, Tanaka Y, et al. Resistance to Erythropoiesis-Stimulating Agents in Pre-Dialysis and Post-Dialysis Mortality in Japanese Incident Hemodialysis Patients. Blood Purif. 2019;47 :31–37.
   PubMed Web of Science ®Google Scholar
• Siami G, Clinton ME, Mrak R, et al. Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron. 1991;57:306–313.
   PubMed Web of Science ®Google Scholar
• Fagher B, Cederblad G, Eriksson M, et al. L-carnitine and haemodialysis: double blind study on muscle function and metabolism and peripheral nerve function. Scand J Clin Laborat Investig. 1985;45:169–178.
   PubMed Web of Science ®Google Scholar
• Hurot JM, Cucherat M, Haugh M, et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002;13:708–714.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Robertson HT, Golper TA, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int. 1990;38:912–918.
   PubMed Web of Science ®Google Scholar
• Eknoyan G, Latos DL, Lindberg J. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis. 2003;41:868–876.
   PubMed Web of Science ®Google Scholar
• Warady BA, Borum P, Stall C, et al. Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol. 1990;10:109–114.
   PubMed Web of Science ®Google Scholar
• Lilien MR, Duran M, Quak JM, et al. Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatric Nephrol (Berlin, Germany). 2000;15:17–20.
   PubMed Web of Science ®Google Scholar
• Sotirakopoulos N, Athanasiou G, Tsitsios T, et al. The influence of l-carnitine supplementation on hematocrit and hemoglobin levels in patients with end stage renal failure on CAPD. Ren Fail. 2002;24:505–510.
   PubMed Web of Science ®Google Scholar
• Kosan C, Sever L, Arisoy N, et al. Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients. Pediatric Nephrol (Berlin, Germany). 2003;18:1184–1188.
   PubMed Web of Science ®Google Scholar
• Verrina E, Caruso U, Calevo MG, et al.; on behalf of the Italian Registry of Pediatric Chronic Dialysis. Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. Pediatr Nephrol. 2007;22:727–733.
   PubMed Web of Science ®Google Scholar
• 2009 Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis. Ther Apher Dial. 2010;14:489–504.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Nishi S, Tomo T, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ren Replace Ther. 2017;3:36.
   Google Scholar
• van Hoeck KJM, Rusthoven E, Vermeylen L, et al. Nutritional effects of increasing dialysis dose by adding an icodextrin daytime dwell to Nocturnal Intermittent Peritoneal Dialysis (NIPD) in children. Nephrol Dial Transplant. 2003;18:1383–1387.
   PubMed Web of Science ®Google Scholar
• Badve SV, Zimmerman DL, Knoll GA, et al. Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics. CJASN. 2008;3:1711–1717.
   PubMed Web of Science ®Google Scholar
• Diaz-Buxo JA, Walker PJ, Chandler JT, et al. Experience with intermittent peritoneal dialysis and continuous cyclic peritoneal dialysis. Am J Kidney Dis. 1984;4:242–248.
   PubMed Web of Science ®Google Scholar
• Venkataraman V, Nolph KD. Utilization of PD modalities: evolution. Semin Dial. 2002;15:380–384.
   PubMed Web of Science ®Google Scholar
• Lo WK, Bargman JM, Burkart J, et al. Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Peritoneal Dial Int. 2006;26:520–522.
   PubMed Web of Science ®Google Scholar
• Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis. 2003;42:1082–1096.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ueda S, Misaki H, et al. Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin Chem. 1994;40:817–821.
   PubMed Web of Science ®Google Scholar
• Aljama P, Bommer J, Canaud B, et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant. 2001;16:22–28.
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Mariak I, Dobrowolska-Zachwieja A. Continuous ambulatory peritoneal dialysis (CAPD) adequacy influences serum free carnitine level. Int Urol Nephrol. 1999;31:533–540.
   PubMedGoogle Scholar
• Fülöp T, Zsom L, Tapolyai MB, et al. Peritoneal dialysis: the unique features by compartmental delivery of renal replacement therapy. Med Hypotheses. 2017;108:128–132.
   PubMed Web of Science ®Google Scholar
• Di Liberato L, Arduini A, Rossi C, et al. L-Carnitine status in end-stage renal disease patients on automated peritoneal dialysis. J Nephrol. 2014;27:699–706.
   PubMed Web of Science ®Google Scholar
• Bonomini M, Zammit V, Pusey CD, et al. Pharmacological use of L-carnitine in uremic anemia: has its full potential been exploited? Pharmacol Res. 2011;63:157–164.
   PubMed Web of Science ®Google Scholar
• Vlassopoulos DA, Hadjiyannakos DK, Anogiatis AG, et al. Carnitine action on red blood cell osmotic resistance in hemodialysis patients. J Nephrol. 2002;15:68–73.
   PubMed Web of Science ®Google Scholar
• Kudoh Y, Aoyama S, Torii T, et al. Long-term effects of oral L-carnitine supplementation on anemia in chronic hemodialysis. Cardiorenal Med. 2014;4:53–59.
   PubMed Web of Science ®Google Scholar
• Lee CT, Chou FF, Chang HW, et al. Effects of parathyroidectomy on iron homeostasis and erythropoiesis in hemodialysis patients with severe hyperparathyroidism. Blood Purif. 2003;21:369–375.
   PubMed Web of Science ®Google Scholar
• Akmal M, Telfer N, Ansari AN, et al. Erythrocyte survival in chronic renal failure. Role of secondary hyperparathyroidism. J Clin Invest. 1985;76:1695–1698.
   PubMed Web of Science ®Google Scholar
• Schiffl H, Lang SM. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients. Nephrol Dial Transplant. 2006;21:133–137.
   PubMed Web of Science ®Google Scholar
• Zachee P, Chew SL, Daelemans R, Lins RL. Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment. Am J Nephrol. 1992;12:188–191.
   PubMed Web of Science ®Google Scholar
• Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997;29:565–568.
   PubMed Web of Science ®Google Scholar
• Horl WH, Jacobs C, Macdougall IC, et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant. 2000;15:43–50.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19 :ii1–47.
   PubMed Web of Science ®Google Scholar
• Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton, Vic). 2007;12:321–330.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant. 2002;17:48–52.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz A, Correa-Rotter R, Vazquez-Rangel A, et al. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin. BMC Nephrol. 2019;20:316.
   PubMed Web of Science ®Google Scholar
• Tsubakihara Y, Nishi S, Akiba T, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Therap Apheresis Dial. 2010;14:240–275.
   PubMed Web of Science ®Google Scholar
• Sibbel SP, Koro CE, Brunelli SM, et al. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients. BMC Nephrol. 2015;16:144.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Abe M, Okada K, et al. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis. Nutrients. 2015;7:3783–3795.
   PubMed Web of Science ®Google Scholar
• Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl. 2012;2:288–291.
   PubMed Web of Science ®Google Scholar
• Bonomini M, Di Liberato L, Zammit V, et al. Current opinion on usage of L-carnitine in end-stage renal disease patients on peritoneal dialysis. Molecules (Basel, Switzerland). 2019;24:3449.
   Web of Science ®Google Scholar
• Suzuki A, Sakai Y, Hashimoto K, et al. Kinetics of carnitine concentration after switching from oral administration to intravenous injection in hemodialysis patients. Ren Fail. 2018;40:196–200.
   PubMed Web of Science ®Google Scholar